University of Oxford's Professor Dame Sarah Gilbert receives Sunhak Peace Prize — Il Sik Hong

She was honoured alongside other new Laureates during a ceremony in South Korea to mark the World Summit 2022 (Summit for Peace on the Korean Peninsula).

Saïd Professor of Vaccinology Sarah Gilbert told the ceremony said: ‘It is a very great honour to be selected to receive the Sunhak Peace Prize, and to follow on from the prestigious laureates who have received the award in previous years. We can achieve so much when we work together, each bringing our different strengths.

‘The work we did to produce the Oxford AstraZeneca vaccine was exhausting and overwhelming at times, but ultimately vital and rewarding. I hope that many young people will be inspired in their career choice by knowing about what we achieved, and that governments and international organisations will work together to ensure that next time we need to respond to a disease threat, we will be better prepared than we were in 2020.’

Gavi, the Vaccine Alliance, was also honoured for its contributions in coordinating COVAX, an initiative aiming to provide fair and equitable access to COVID-19 vaccines worldwide.

The biennial Sunhak Peace Prize was founded in 2013 and honours individuals and organizations that have demonstrated service service to global peace and well-being in one of three areas - sustainable human development, conflict resolution or ecological conservation.

Dr Hak Ha Jan Moon created the prize to honour the legacy of her late husband, Rev Dr Sun Myung Moon, who dedicated his life to build a global culture of peace with the theme, ‘One Family Under God.’

 / People / Sarah Gilbert

CONTACT INFORMATION Website The Jenner Institute

Address Old Road Campus Research Building

COLLAORATION

Beware: points on the map are generated from user entered data and may not always be accurately located

Adrian Hill Jenner Institute, Oxford University, Old Road Campus Research Building, United Kingdom

Teresa Lambe Jenner Institute, Oxford University, Centre for Clinical Vaccinology and Tropical Medicine, United Kingdom

Catherine Green Wellcome Trust Centre for Human Genetics, Oxford University, Henry Wellcome Building of Genomic Medicine, United Kingdom

Katie Ewer Jenner Institute, Oxford University, Old Road Campus Research Building, United Kingdom

All Collaborations

Podcast ‘Viral vectored vaccine development’

How the ‘flu vaccine works - as shown on the BBC news website.

The Clinical Biomanufacturing Facility, University of Oxford

arah Gilert SAÏD PROFESSORSHIP OF VACCINOLOGY (DBE)

Dame Commander of the Most Excellent Order of the British Empire (DBE), for services to Science and Public Health.

For more than fifteen years we have been making and testing vaccines designed to induce T cell responses

to the antigens we encode, initially using antigens from malaria, influenza and tuberculosis. We have had most success with heterologous prime-boost regimes using either a DNA vaccine or recombinant fowlpox or adenovirus to prime a response and recombinant MVA (Modified Vaccinia Ankara) to boost it.

Recombinant adenoviruses for clinical trials can now be produced to GMP by the University’s Clinical Biomanufacturing Facility. Staff at the CBF work closely with academics to prepare batches of new vaccines for clinical trials.

Two new vaccines (MVA-NP+M1 and ChAdOx1 NP+M1) have been developed to target Influenza A. Adults already have memory T cell responses to ‘flu antigens, but over time these fall below protective levels. In clinical trials, the new vaccines are able to boost these low-level responses to very high levels, either alone or in combination with the seasonal ‘flu vaccine. The enhanced T cell responses could be protective against multiple Influenza subtypes.

Recent work has focused on developing vaccines against emerging and re-emerging pathogens, including MERS, Lassa, Nipah and CCHF. A vaccine against MERS (Middle East Respiratory Syndrome) has been tested in clinical trials in the UK, and is now in trials in Saudi Arabia, where the virus is endemic.

We are currently focusing on developing a vaccine (ChAdOx1 nCoV-19) against SARS-CoV-2 working with OVG and teams within the Jenner including those led by Teresa Lambe and Katie Ewer.

COVID-19 Vaccine Trial Uk

I am a co-founder of the University’s Oxford spin in–out company Vaccitech, which is developing novel vaccines using the non-replicating viral vectors Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA).

KY PULICATION

Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral- vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.

Journal article

Folegatti PM. et al, (2020), The Lancet. Infectious diseases, 20, 816 - 826

A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques

Journal article

van Doremalen N. et al, (2020), Science Advances, 6

RCNT PULICATION

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Journal article

Clemens SAC. et al, (2021), Nature Communications, 12

Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice

Journal article

Spencer AJ. et al, (2021), Nature Communications, 12

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Journal article

Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040

ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.

Journal article

Fischer RJ. et al, (2021), Nature communications, 12

No one is safe until we are all safe.

Journal article

Gilbert S. and Hatchett R., (2021), Science translational medicine, 13

More publications

Home Site Map Contact Freedom of Information Privacy Policy Copyright Accessibility Medical Sciences Division Cookies on this website Oxford University @NDMOxford @JennerInstitute @vaccinetrials Jenner Institute Vaccine trials We use cookies to ensure that we give you the best experience on our website. If you click ‘Continue’ we’ll assume that you are happy to receive all

cookies and you won’t see this message again. Click ‘Find out more’ for information on how to change your cookie settings. Log in Continue